US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Syros Pharmaceuticals Inc (0LC7) 銘柄情報

Syros Pharmaceuticals Inc (0LC7)

11.96

0.00

(0.00%)

終了 6月12日 12:30AM

Syros Pharmaceuticals Inc (0LC7) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

11.96

( - )

買値

11.96

売値

11.96

出来高

0.00

0.00 日の範囲 0.00

11.96 52 週間の範囲 11.96

時価総額

前日終値

11.96

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 11,150

発行済株式数

26,832,457

配当利回り

PER

-0

1 株当たり利益 (EPS)

-2.66

歳入

386k

純利益

-97.82M

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subse... Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.syros.com

本社

Cambridge, United States

設立

2026

Syros Pharmaceuticals Inc is listed in the sector of the ロンドン証券取引所 with ticker 0LC7. The last closing price for Syros Pharmaceuticals was US$11.96. Over the last year, Syros Pharmaceuticals shares have traded in a share price range of US$ 11.96 to US$ 11.96.

Syros Pharmaceuticals currently has 26,832,457 shares in issue. The market capitalisation of Syros Pharmaceuticals is US$320.92 million. Syros Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.00.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	11.96	11.96	11.96	4210	11.96	DE
26	0	0	11.96	11.96	11.96	2391	11.96	DE
52	0	0	11.96	11.96	11.96	3043	11.96	DE
156	0	0	11.96	11.96	11.96	84504	11.96	DE
260	0	0	11.96	11.96	11.96	49554	11.96	DE

0LC7 - Frequently Asked Questions (FAQ)

What is the current Syros Pharmaceuticals Inc share price?

The current share price of Syros Pharmaceuticals Inc is US$ 11.96

How many Syros Pharmaceuticals Inc shares are in issue?

Syros Pharmaceuticals Inc has 26,832,457 shares in issue

What is the market cap of Syros Pharmaceuticals Inc?

The market capitalisation of Syros Pharmaceuticals Inc is USD 320.92M

What is the 1 year trading range for Syros Pharmaceuticals Inc share price?

Syros Pharmaceuticals Inc has traded in the range of US$ 11.96 to US$ 11.96 during the past year

What is the PE ratio of Syros Pharmaceuticals Inc?

The price to earnings ratio of Syros Pharmaceuticals Inc is -0

What is the cash to sales ratio of Syros Pharmaceuticals Inc?

The cash to sales ratio of Syros Pharmaceuticals Inc is 0.03

What is the registered address of Syros Pharmaceuticals Inc?

The registered address for Syros Pharmaceuticals Inc is 35 CambridgePark Drive, Cambridge, Massachusetts, 02140

What is the Syros Pharmaceuticals Inc website address?

The website address for Syros Pharmaceuticals Inc is www.syros.com

vlispxpert

vlispxpert 5分前

aaahh trump cancels strike, nice timing for market lol

price_and_volume

price_and_volume 5分前

7.5B after two 1:1000 RS last several years...

O/S has doubled since @Jane1999 brought $TWOH to everyone's attention nearly 18 months ago.

2025 was fun, but the shares keep comin'...

https://investorshub.advfn.com/uimage/uploads/2026/6/11/dgiocScreenshot

RIGATONI

RIGATONI 5分前

Wake up on this one...

SHMN .0015

updates overdue...

Last news, quite some time ago>

SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug D

Porch Honkey

Porch Honkey 5分前

In total, the insiders bought 196.6M and sold 0 GTCH shares in the last 46 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades. No statistically significant buy or sell signals detected in recent insider data.

LTListener

LTListener 5分前

Bottom of post 58043 from mexi. I believe it is unrelated to KRM-ll-81 and just an artifact of some internet search/copy paste is my guess.

BigBadWolf

BigBadWolf 6分前

Financial Volume $100,830 VWAP 0.001211
Time Price Size Type B/S Bid Price Ask Price Buy Ind. Total Volume Num Exch.
13:54:27 0.0012 2,501,400 Buy 0.0011 0.0012 83,227,170 119 nasd

Mozy429

Mozy429 7分前

And he’s been wrong about 95-% of the time with his nonsense.

Preciouslife1

Preciouslife1 7分前

https://www.mexc.com/news/1140539XRP EXPLAINED

Coo breeze

Coo breeze 7分前

Exactly they need to be much more transparent, much more, who's going to tell them ?

otcstardmn

otcstardmn 7分前

some impatient long term holders selling out on the bids..still thin for a huge upside once new eyes on this

HenryB3

HenryB3 7分前

The Scam is running its course. The bagholders are realizing, its all nonsense. Kick the can down the road even further. To when? How's 2029? That buys a few more years to sell worthless stock to a bunch of kool aide drinkers. The trajectory is south. Red flags have always been flying, just that

mikeo56

mikeo56 7分前

BOOM 830 k gone , bought in 1 trade

Porch Honkey

Porch Honkey 7分前

I Strongly disagree with you, lol.

fredscott36

fredscott36 8分前

.....dude: in the event, FCNCA were taken over by USB, in a stock deal (or cash/stock option, but assume stock)...........OUR FCNCA STOCK WOULD BE CONVERTED INTO U.S. BANK common stock......................math..........and would continue to be held in trust.............f/b/o...........UWBI cusip ho

vlispxpert

vlispxpert 8分前

I'll keep RDW on radar

LOB

$0.0105+$0.0013(+13.64%)
Market open: 1:42:49 PM ET, 06/11/2026
Bid
$0.0102
Ask
$0.0105
Bid/Ask Size
10,000/20,000
Previous close
$0.0092
Today's open
$0.0092
Today's volume
4.2M
Below Avg.

jobynimble

jobynimble 8分前

Why do you care when you posted you’re not buying it back? What are you trying to prove?

chill-will 1

chill-will 1 8分前

Keep hope alive

WhatMoney?

WhatMoney? 8分前

Regardless though, sitting here whining amd complaining about it isn't going to change anything which is why I say ti give them the benefit of the doubt. Obviously you've done that thus far with the amount of shares you currently hold.

Gamco

InterDigital pact could yield $40M-$80M in recurring revenue, says William Blair
TheFly - Jun 11, 2026, 12:35 PM

After InterDigital (IDCC) announced that it had entered into a video services and devices licensing agreement with Amazon (AMZN), the terms of which will be determin

chen1992

chen1992 9分前

Great and all JAB!

Question now is, do they R/M post FID 1? Or post FID 2 and/or 3?

Wallstreeter$$$

Wallstreeter$$$ 9分前

JS submitted the EFS IDE as the best option so some random goof whining abt it is worthless trash. Clearer now!?

meixatech

meixatech 9分前

Perampanel (brand name Fycompa) is an antiseizure medication. Common side effects include dizziness, somnolence (sleepiness), fatigue, irritability, falls, and nausea. Psychiatric and coordination issues—like aggression, vertigo, and balance problems—are also prevalent, especially with rapid dose in

otcstardmn

otcstardmn 9分前

$ATWT 500% rise easy from no revenue. to millions incoming

Trooperstocks

Trooperstocks 9分前

$MAJI - Acquisition adds $135,000 in immediate monthly recurring baseline revenue
*Total $8 million purchase price with performance-based $1 million bonus structure
*Transaction intended to be non-dilutive to existing MAJI shareholders
*Funding expected from proceeds of LMMY sha

Syros Pharmaceuticals

3355% until 02/27/2035

iShares EUR High Yield C...

Global X Nasdaq 100 Inde...

Colony Credit Real Estate

Sparebanken Sor

Charlton Aria Acquisition

Taiyo Yuden (PK)

Bmo Core Plus Bond Fund ...

ZKB Gold Corporate (EM)

Waskahigan Oil and Gas

iShares iBonds Dec 2029 ...

SÃO MARTINHO ON

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。